H.C. Wainwright analyst Debjit Chattopadhyay views Sarepta Therapeutics' collaboration with Roche (RHHBY) as a "robust validation" of SRP-9001. Further, given the "compelling" economics for the outside the U.S. rights, the deal might be indicative of functional benefits, "which potentially go above and beyond the evidence from longitudinal natural history studies," Chattopadhyay tells investors in a research note. The analyst points out that all 40 subjects in the SRP-9001 clinical study are expected to be dosed by the end of 2019, setting the stage for functional data readout during late 2020, and that management expects to commence dosing in its commercial supply study by mid-2020. SRP-9001 provides the "perfect complement" to Roche's neurology/neuromuscular franchise, says Chattopadhyay, who reiterates a Buy rating on Sarepta with a $260 price target. The stock in premarket trading is up 11% to $140.00.